Abstract:Fungal keratitis (FK) is a severe infectious corneal disease. Since traditional eye drops exhibit poor dissolution and high corneal toxicity, the efficacy of current treatments for FK remains limited. It is needed to develop new approaches to control the cornea damage from FK. In this study, a nanobody (Nb) specific to β-glucan in the fungal cell wall was prepared. The conjugate of the Nb with natamycin (NAT), a traditional antifungal drug, was synthesized. Firstly, we found the Nb specific to β-glucan inhibited fungal growth by disrupting cell wall and biofilm formation.. In addition, the content of β-glucan in the fungal cell wall decreased after Nb treatment. The Nb also reduced the adhesion ability of fungal conidia to human corneal epithelial cells (HCECs). Further, we examined the difference between NAT and Nb-NAT in antifungal growth. Nb-NAT showed better antifungal effects than NAT which was caused by the interaction between Nb and β-glucan. Moreover, Nb concentration below 0.5 mg/mL did not affect the viability of HCECs. Nb-NAT had less cytotoxicity and ocular surface irritation than NAT. Nb specific to β-glucan attenuated Aspergillus fumigatus ( A. fumigatus ) virulence and relieved inflammatory responses in FK. Nb-NAT treatment of the cornea improved therapeutic effects compared with NAT. It decreased clinical scores and expression level of inflammatory factors. To our knowledge, this study is the first to report a Nb specific to β-glucan and Nb-NAT for the treatment of FK. These unique functions of the Nb specific to β-glucan and Nb-NAT would render it as an alternative molecule to control fungal infections including FK. Statement of Significance Fungal keratitis is a corneal disease with a high rate of blindness. Due to the poor dissolution and high corneal toxicity exhibited by traditional eye drops, the efficacy of current therapeutic treatments for fungal keratitis (FK) remains limited. To enhance the therapeutic effect of natamycin in treating fungal keratitis, this study developed an innovative approach by preparing a β-glucan-specific nanobody and loading it with the antifungal drug natamycin. The β-glucan-specific nanobody has the ability to control both fungal pathogen invasion and inflammation, which can cause damage to the cornea in FK. The conjugation with the β-glucan-specific nanobody significantly increased the antifungal capacity of natamycin and reduced its toxicity. The further application of natamycin conjugated with the β-glucan-specific nanobody could be expanded to other diseases caused by fungal pathogen infections.

Clinical evaluation of 67Ga scanning in the diagnosis of anaplastic carcinoma and malignant lymphoma of the thyroid.

Feasibility, safety and clinical utility of angiography in patients with suspected pulmonary embolism

Thermosensitive Tri-Block Polymer Nanoparticle-Hydrogel Composites as Payloads of Natamycin for Antifungal Therapy Against Fusarium Solani

Macrophage Membrane-Coated Nanoparticles for the Delivery of Natamycin Exhibit Increased Antifungal and Anti-Inflammatory Activities in Fungal Keratitis

Infant twin mortality and hospitalisations after the perinatal period – a prospective cohort study from Guinea‐Bissau

The Preparation and Therapeutic Effects of β-Glucan-Specific Nanobodies and Nanobody-Natamycin Conjugates in Fungal Keratitis

Ethosomal Nanoformulations for Combinational Photothermal Therapy of Fungal Keratitis

Evaluation of adrenal masses with gadolinium enhancement and fat‐suppressed MR imaging

Breaking Down the Barriers of Drug Resistance and Corneal Permeability with Chitosan-Poly(ethylene glycol)-LK13 Peptide Conjugate to Combat Fungal Keratitis

Multifunctional natamycin modified chondroitin sulfate eye drops with anti-inflammatory, antifungal and tissue repair functions possess therapeutic effects on fungal keratitis in mice

Therapeutic effect of oxidized bletilla striata polysaccharide-natamycin eye drops on fungal keratitis

Laccase-mediated functionalization of natamycin by gallic acids for the therapeutic effect on Aspergillus fumigatus keratitis

Overcoming the Stromal Barrier of the Cornea with a Peptide Conjugate Nano‐assembly to Combat Fungal Keratitis

Physiochemical Characterization of Lipidic Nanoformulations Encapsulating the Antifungal Drug Natamycin

The combined utilization of Chlorhexidine and Voriconazole or Natamycin to combat Fusarium infections

Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery

Comparative Evaluation of Topical Monotherapy (Natamycin or Natasol) and Combination Therapy (Natamycin and Voriconazole) in Mild-Moderate Fungal Keratitis

Clinical efficacy of cyclosporin and natamycin for fungal keratitis

Engineered bio-adhesive polyhedral oligomeric silsesquioxane hybrid nanoformulation of amphotericin B for prolonged therapy of fungal keratitis

Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis

Fabrication of nanozyme-thixotropic anionic hydrogel coating with multi-enzyme-mimicking activity for the treatment of fungal keratitis